The UK's Acacia Pharma has raised $10 million in its first round. New investor Lundbeckfond Ventures joins Gilde Healthcare in this Series A financing, which is being earmarked for the Phase II development of its two lead products: APD421 for the prevention of nausea & vomiting in post-surgical patients and APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients. Acacia release
Read the full article at FierceBiotech
